News
For the most recent news and press releases, visit our investor relations website: www.ir.icecure-medical.com
IceCure Medical Announces Updated Regulatory Strategy in China for the IceSense3® System to Treat Cancerous Tumors with Cryoablation
IceCure submitted an amendment to the registration certificate granted for the IceSense3 System by China’s NMPA, which will allow IceCure to sell its IceSense3 and
IceCure Medical Reports Financial Results for the First Half of 2021 and Recent Operating Highlights
CAESAREA, Israel, September 23, 2021 — IceCure Medical Ltd. (NASDAQ: ICCM) (TASE: ICCM) (“IceCure” or the “Company”), developer of the next generation minimally invasive cryoablation
IceCure Medical Announces First Peer Reviewed Publication for the 3-Year Interim Analysis of the ICE3 Trial on Cryoablation of Low-Risk, Early-Stage Breast Cancer
IceCure Medical Ltd. (NASDAQ: ICCM) (TASE: ICCM) announced that the first peer reviewed article “Cryoablation Without Excision for Low-Risk, Early-Stage Breast Cancer: 3-Year Interim Analysis of Ipsilateral Breast Tumor Recurrence in the ICE3 Trial” was published in the Annals of Surgical Oncology with Dr. Richard Fine, MD, FACS, an ICE3 investigator who serves as Program Director of the Breast Surgical Oncology Fellowship and as Director of Research and Education at the West Comprehensive Breast Center in Germantown, TN, as the lead author.
IceCure Medical Announces Exclusive Distribution Agreement to Sell ProSense™ Cryoablation System in Turkey
CAESAREA, Israel, September 1, 2021 — IceCure Medical Ltd. (NASDAQ: ICCM) (TASE: ICCM) (“IceCure” or the “Company”), developer of the next generation minimally invasive cryoablation
IceCure Medical Shares to Begin Trading on Nasdaq Capital Market on August 26, 2021
IceCure Medical Ltd. (NASDAQ: ICCM) (TASE: ICCM) (“IceCure” or the “Company”), developer of the next generation minimally invasive cryoablation technology that destroys tumors by freezing, today announced that its ordinary shares have been approved for listing on the Nasdaq Capital Market (“Nasdaq”). The Company’s shares will begin trading on Nasdaq on today, August 26, 2021, at market open, under the ticker symbol “ICCM.”
ICECURE GIVES NOTICE OF SPECIAL GENERAL MEETING FOR COMPANY SHAREHOLDERS SEPTEMBER 13 2021
Notice is hereby given of the convening of a special general meeting for the shareholders of IceCure to be held on Monday, September 13, 2021
IceCure Medical Announces Updated Regulatory Strategy in China for the IceSense3® System to Treat Cancerous Tumors with Cryoablation
IceCure submitted an amendment to the registration certificate granted for the IceSense3 System by China’s NMPA, which will allow IceCure to sell its IceSense3 and
IceCure Medical Reports Financial Results for the First Half of 2021 and Recent Operating Highlights
CAESAREA, Israel, September 23, 2021 — IceCure Medical Ltd. (NASDAQ: ICCM) (TASE: ICCM) (“IceCure” or the “Company”), developer of the next generation minimally invasive cryoablation
IceCure Medical Announces First Peer Reviewed Publication for the 3-Year Interim Analysis of the ICE3 Trial on Cryoablation of Low-Risk, Early-Stage Breast Cancer
IceCure Medical Ltd. (NASDAQ: ICCM) (TASE: ICCM) announced that the first peer reviewed article “Cryoablation Without Excision for Low-Risk, Early-Stage Breast Cancer: 3-Year Interim Analysis of Ipsilateral Breast Tumor Recurrence in the ICE3 Trial” was published in the Annals of Surgical Oncology with Dr. Richard Fine, MD, FACS, an ICE3 investigator who serves as Program Director of the Breast Surgical Oncology Fellowship and as Director of Research and Education at the West Comprehensive Breast Center in Germantown, TN, as the lead author.
IceCure Medical Announces Exclusive Distribution Agreement to Sell ProSense™ Cryoablation System in Turkey
CAESAREA, Israel, September 1, 2021 — IceCure Medical Ltd. (NASDAQ: ICCM) (TASE: ICCM) (“IceCure” or the “Company”), developer of the next generation minimally invasive cryoablation
IceCure Medical Shares to Begin Trading on Nasdaq Capital Market on August 26, 2021
IceCure Medical Ltd. (NASDAQ: ICCM) (TASE: ICCM) (“IceCure” or the “Company”), developer of the next generation minimally invasive cryoablation technology that destroys tumors by freezing, today announced that its ordinary shares have been approved for listing on the Nasdaq Capital Market (“Nasdaq”). The Company’s shares will begin trading on Nasdaq on today, August 26, 2021, at market open, under the ticker symbol “ICCM.”
ICECURE GIVES NOTICE OF SPECIAL GENERAL MEETING FOR COMPANY SHAREHOLDERS SEPTEMBER 13 2021
Notice is hereby given of the convening of a special general meeting for the shareholders of IceCure to be held on Monday, September 13, 2021